CRISPR gene-editing therapy delivers dramatic triglyceride reductions in a world first

A one-and-done shot at fixing sky-high triglycerides

For the first time ever, a CRISPR-Cas9 gene-editing therapy has been used to treat severe hypertriglyceridemia — and the early results are turning heads. CTX310 (CRISPR Therapeutics), a single IV dose targeting the liver gene ANGPTL3, produced dramatic reductions in triglycerides and related lipid markers at 30 days in a phase 1b study of 10 patients. The study was presented at the American Heart Association Scientific Sessions in Chicago.

The therapy's appeal is straightforward: one treatment, potentially lasting results. Unlike currently approved options — a monthly injection (olezarsen) or a quarterly shot (plozasiran) — CTX310 is designed to work just once. Experts say this could be a game-changer for patients who struggle with repeat dosing or face extremely high cardiovascular and pancreatitis risk.

By the Numbers

• Median triglyceride reduction at 30 days: –62.8%
• ANGPTL3 reduction: –65.3%
• Non-HDL reduction: –50.9%; LDL: –16.4%; ApoB: –23.4%
• 3 of 9 responders saw triglycerides drop by >80%
• No serious adverse events reported; only 4 mild-to-moderate adverse events total

Why it matters: Severe hypertriglyceridemia carries serious risks — acute pancreatitis and cardiovascular disease chief among them. A one-time gene-editing therapy could transform how clinicians manage this difficult-to-treat condition, offering a compelling alternative for patients who need durable, low-burden treatment options.